Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cantargia ABCHIX:CANTAS 33 EV-to-EBITDA is 2.17 as of Jul. 31, 2026, which is 43% below its 10-year median of 3.80. GuruFocus rates CHIX:CANTAS with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 411 Biotechnology companies, Cantargia AB ranks better than 71.05% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Cantargia AB's enterprise value is kr392.0 Mil.
Cantargia AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was kr180.6 Mil. Therefore, Cantargia AB's EV-to-EBITDA for today is 2.17.
The historical rank and industry rank for Cantargia AB's EV-to-EBITDA or its related term are showing as below:
CHIX:CANTAs'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 1.1 Med: 3.8 Max: 7.69
Current: 2.11
During the past 13 years, the highest EV-to-EBITDA of Cantargia AB was 7.69. The lowest was 1.10. And the median was 3.80.
CHIX:CANTAs's EV-to-EBITDA is ranked better than 71.05% of 411
companies
in the Biotechnology industry
Industry Median: 12.05
vs CHIX:CANTAs: 2.11
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Cantargia AB (CHIX:CANTAs) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cantargia AB's PE Ratio (TTM) for today is calculated as:
Cantargia AB's share price for today is kr4.174.
Cantargia AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.650.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Cantargia AB's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:CANTAS vs VRTX, REGN, RVMD: EV-to-EBITDA Comparison
For the Biotechnology subindustry, Cantargia AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cantargia AB EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cantargia AB's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Cantargia AB's EV-to-EBITDA falls into.
Cantargia AB's current Enterprise Value is kr392.0 Mil.
Cantargia AB's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr180.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cantargia AB (CHIX:CANTAS) has a EV-to-EBITDA of 2.17 as of Jul. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cantargia AB. This is 43% below median its historical median of 3.80. Over the past decade, Cantargia AB's EV-to-EBITDA has ranged from 1.10 to 7.69. According to the industry distribution chart, Cantargia AB ranks #119 out of 411 companies in the Biotechnology industry, placing it in the top 29%.
Is Cantargia AB's EV-to-EBITDA too high?
Cantargia AB's current EV-to-EBITDA of 2.17 is 43% below median its 10-year median of 3.80. Over the past 10 years, this metric has ranged from a low of 1.10 to a high of 7.69. The Biotechnology industry median EV-to-EBITDA is 12.05. Cantargia AB's value of 2.17 is 82% below this industry median. Based on the distribution chart, Cantargia AB ranks #119 out of 411 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cantargia AB has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Cantargia AB's EV-to-EBITDA compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cantargia AB ranks #119 out of 411 companies for EV-to-EBITDA. This puts Cantargia AB in the upper half of its industry. The industry median EV-to-EBITDA is 12.05. Cantargia AB's value of 2.17 is 82% below this benchmark. Historically, Cantargia AB's own EV-to-EBITDA has ranged from 1.10 to 7.69 over the past decade. While the company's 10-year median is 3.80 vs. the industry median of 12.05, Cantargia AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 12.05, based on 411 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cantargia AB's current EV-to-EBITDA of 2.17 is 82% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Cantargia AB. For the Biotechnology industry, the median EV-to-EBITDA is 12.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cantargia AB's current EV-to-EBITDA is 2.17, which is 43% below median its own 10-year median of 3.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cantargia AB stock overvalued right now?
Cantargia AB (CHIX:CANTAS) has a current EV-to-EBITDA of 2.17. The current EV-to-EBITDA is 2.17, which is 43% below median its 10-year median of 3.80 and 82% below the Biotechnology industry median of 12.05. Cantargia AB's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Cantargia AB (CHIX:CANTAS), the current EV-to-EBITDA is 2.17 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cantargia AB is a Swedish biotech company that develops targeted antibody-based drugs for cancer as well as autoimmune and inflammatory diseases. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's development programme includes the candidate drugs nadunolimab (CAN04) and CAN10, both in the clinical development stage, which were latter acquired by Otsuka Pharmaceutical in 2025. In addition, the company is also developing a a pre-clinical project CAN14, derived from antibody platform CANxx. Geographically, the company's revenues have been generated in the markets of Japan and United States.
33GF Score
Get the complete analysis for CHIX:CANTAS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:CANTAS has been successfully added to your 
